Table 1.
Study, year [reference] | N | Intervention | Control | Delirium occurrence | Duration of mechanical ventilation | Length of stay—ICU | Length of stay—hospital | Mortality | Arrhythmia | Risk of bias* |
---|---|---|---|---|---|---|---|---|---|---|
Abbasi 2018 [34] | 137 | Melatonin PO | Placebo PO | + | + | + | + | + | Low | |
Abdelgalel 2016 [35] | 90 | Dexmedetomidine IV infusion with optional LD | Placebo IV intermittent | + | + | + | + | + | Low | |
Al-Qadheeb 2016 [36] | 68 | Haloperidol IV intermittent | Placebo IV intermittent | + | + | + | Low | |||
Azeem 2018 [38] | 60 | Dexmedetomidine IV LD + infusion | Morphine IV + midazolam IV | + | + | + | Low | |||
vanden Boogaard 2018 [40] | 1789 | Haloperidol IV intermittent | Placebo IV intermittent | + | + | + | + | + | Low | |
Chang 2018 [43] | 60 | Dexmedetomidine IV infusion | Propofol IV infusion | + | + | High | ||||
Chanques 2017 [44] | 137 | IV sedation interruption | Usual sedation | + | + | + | + | + | High | |
DeJonghe 2018 [49] | 1174 | IV sedation protocol | Usual sedation | + | + | High | ||||
Devlin 2014 [50] | 33 | Dexmedetomidine IV infusion | Placebo IV infusion | + | + | + | + | Low | ||
Djaiani 2016 [51] | 183 | Dexmedetomidine IV LD + infusion | Propofol IV infusion | + | + | + | + | + | Low | |
Gandolfi 2020 [55] | 203 | Melatonin PO | Placebo PO | + | + | + | + | Low | ||
Girard 2008 56] | 336 | IV sedation interruption | Usual sedation | + | + | + | High | |||
Hakim 2012 [59] | 101 | Risperidone PO | Placebo PO | + | + | + | + | Low | ||
Hu 2015 [60] | 76 |
Intervention 1: dexmedetomidine IV infusion + propofol IV infusion Intervention 2: propofol IV infusion |
Midazolam IV infusion | + | High | |||||
Huang 2014 [61] | 108 | Dexmedetomidine IV infusion | Propofol IV infusion | + | + | High | ||||
Hughes 2021 [62] | 432 | Dexmedetomidine IV infusion | Propofol IV infusion | + | Low | |||||
Javaherforooh Zadeh 2021 [63] | 60 | Melatonin PO | Placebo PO | + | + | High | ||||
Kawazoe 2017 [67] | 201 | Dexmedetomidine IV infusion | Sedation IV infusion without dexmedetomidine | + | + | + | + | + | + | High |
Khan 2018 [69] | 135 | Haloperidol IV intermittent dose | Placebo IV intermittent dose | + | + | + | + | + | Low | |
Li 2016 [71] | 70 | 3 groups of dexmedetomidine, propofol or combination IV infusion to circadian clock | Sedation IV infusion without regulation to circadian clock | + | + | + | High | |||
Liu 2017 [73] | 105 |
Intervention 1: remifentanil IV + midazolam IV infusions Intervention 2: fentanyl + midazolam IV infusions |
Placebo + midazolam IV infusion | + | + | + | + | Low | ||
Lyu 2015 [74] | 140 | Remifentanil + midazolam IV infusion | Midazolam IV infusion | + | + | + | + | High | ||
Mehta 2012 [76] | 423 | Protocolized sedation + daily interruption | Protocolized sedation | + | + | + | + | + | High | |
Mokhtari 2020 [79] | Aripiprazole PO | Placebo PO | + | + | High | |||||
Nassar 2014 [81] | Daily IV sedation interruption | Intermittent IV sedation | + | + | + | + | High | |||
Nishikimi 2018 [82] | 88 | Ramelteon PO | Placebo PO | + | + | + | Low | |||
Pandharipande 2007 [85] | 103 | Dexmedetomidine IV LD + infusion | Lorazepam IV LD + infusion | + | + | + | Low | |||
Park 2014 [86] | 142 | Dexmedetomidine IV LD + infusion | Remifentanil IV infusion | + | + | High | ||||
Prakanrattana 2007[89] | 126 | Risperidone PO | Placebo PO | + | + | + | + | Low | ||
Priye 2015 [90] | 64 | Dexmedetomidine IV infusion | Placebo IV infusion | + | Low | |||||
Rubino 2010 [93] | 30 | Clonidine IV LD + infusion | Placebo IV infusion | + | + | + | Moderate | |||
Ruokonen 2009 [94] | 85 | Dexmedetomidine IV infusion | Propofol or midazolam IV infusion | + | Low | |||||
Shehabi 2009 [97] | 299 | Dexmedetomidine IV infusion | Morphine IV infusion | + | + | + | + | + | + | Low |
Shehabi 2013 [98] | 37 | Early goal directed sedation Dexmedetomidine IV infusion | Propofol or midazolam IV infusion | + | + | + | + | High | ||
Shehabi 2019 [99] | 4000 | Dexmedetomidine IV infusion | Propofol or midazolam IV infusion | + | + | + | + | + | High | |
Shu 2019 [100] | 80 | Dexmedetomidine IV LD + infusion | Midazolam IV infusion | + | High | |||||
Skrobik 2018 [102] | 100 | Dexmedetomidine IV infusion | Placebo IV infusion | + | + | + | + | Low | ||
Song 2015 [103] | 90 | Dexmedetomidine IV infusion | Midazolam IV infusion | + | + | + | High | |||
Spies 2011 [105] | 60 | Remifentanil IV infusion | Fentanyl IV infusion | + | + | Low | ||||
Strom 2010 [106] | 113 | No sedation; analgesia with opioid | Analgesia with opioid + propofol IV infusion | + | + | High | ||||
Su 2016 [107] | 700 | Dexmedetomidine IV infusion | Placebo IV infusion | + | + | + | + | + | + | Low |
Wan 2011 [112] | 200 | Dexmedetomidine IV infusion | Midazolam IV infusion | + | + | High | ||||
Wang 2012 [113] | 457 | Haloperidol IV infusion | Placebo IV infusion | + | + | + | + | + | + | Low |
See supplementary eTables 2 and 3 for detailed description of included studies and risk of bias assessment
IV intravenous, LD loading dose, PO per os
*The overall risk of bias was the lowest for any domain in the risk of bias tool (i.e., sequence generation, allocation concealment, incomplete outcome data, selective reporting, or other bias)